SG1906
SG1906 is an innovative bi-specific antibody therapeutic biological candidate developed by CNBG-Sumgen. It has received IND clearance from both FDA and NMPA and a Ph I clinical trial for the treatment of late stage solid tumor is ongoing in China.
